A1: no patient specific details have been provided.Therefore, the patient initials reflect the w.L.Gore internal case number.H3: as the device was discarded on site, no further investigation of the device can be performed.Product history review: a review of the manufacturing records indicated the lots met all pre-release specifications.Imaging evaluation: the identity of the device was provided and the examination of the device history record did not identify any potential root causes attributable to the manufacture of the device.The images provided were not adequate to confirm the case description.The reported failure mode reflects the case description but could not be confirmed.The evaluation found no anomalies attributable to the manufacture of the device.Heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
It was reported to gore that the patient underwent surgical treatment for dialysis access as a brachio-basilic connection on (b)(6) 2023, with a gore® acuseal vascular graft.Due to a stenosis (observed by dialysis staff) the patient was sent to the radiologist for percutaneous transluminal angioplasty (pta) and a dissection /delamination was observed in part of the vascular graft.This part of the gore® acuseal vascular graft was removed / explanted by the physician on (b)(6) 2024.The physician stated that from the draining part, a puncture hole was visible with destruction of the inner layer, from which the dissection began.He confirmed that the patient is cannulated using the rope ladder technique; graft was punctured at a different location every dialysis session.
|